OlegEAkilovMDPhD

Dermatology • Pittsburgh, PA

Assistant Professor of Dermatology; Director, Cutaneous Lymphoma Program

Join to view full profile

Dr. Akilov is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Akilov's full profile

Already have an account?

Office
200 Lothrop St
# Univ
Pittsburgh, PA 15213
Phone+1 412-647-4200

Fax+1 412-864-3740

Education & Training

UPMC Medical EducationResidency, Dermatology, 2012 - 2015
UPMC Medical EducationChief Residency, Dermatology, 2014 - 2014
University of ColoradoInternship, Surgery, 2011 - 2012
UPMC Medical Education/Presbyterian Shadyside HospitalFellowship, Cutaneous Oncology, 2009 - 2011
Ural State Medical AcademyClass of 1998

Certifications & Licensure

PA State Medical License 2009 - 2024
CO State Medical License 2011 - 2014
American Board of Dermatology Dermatology

Clinical Trials

Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research Start of enrollment: 2004 Oct 01
Recruiting

Publications & Presentations

PubMed

13 citations
The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1
Oleg Kruglov, Xuesong Wu, Samuel T Hwang, Oleg E. Akilov
Blood Advances. 2020-10-13
367 citations
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H. Miles Prince, Youn H. Kim, Steven M. Horwitz, Reinhard Dummer, Julia Scarisbrick
Lancet. 2017-08-05
79 citations
Clinical manifestations and classification of Old World cutaneous leishmaniasis.
Oleg E. Akilov, Amor Khachemoune, Tayyaba Hasan
International Journal of Dermatology. 2007-02-01

Lectures

Intralesional Administration of the CD47 Antagonist TTI-621 (SIRPαFc) Induces Responses in Both Injected and Non-Injected Lesions in Patients with Relapsed/Refractory ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the P...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018